ArticleAntimicrobial agents and chemotherapy1997
Evaluation of selected antiprotozoal drugs in the Babesia microti-hamster model.
Article in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Targeting piroplasmosis and theileriosis: New frontiers in drug development.Tropical animal health and production · 2025Pooled it
- Tafenoquine: A Breakthrough Option for Babesiosis Treatment.Tropical medicine and infectious disease · 2026Article
- A Divergent Synthesis of Numerous Pyrroloiminoquinone Alkaloids Identifies Promising Antiprotozoal Agents.Journal of the American Chemical Society · 2024Article
- Tafenoquine for Relapsing Babesiosis: A Case Series.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Comparative chemical genomics inProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis.The Journal of infectious diseases · 2024Article
- Unrevealing the therapeutic potential of artesunate against emerging zoonoticFrontiers in veterinary science · 2024Article
- Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with AcutePathogens (Basel, Switzerland) · 2023Article
- Evaluation of the Inhibitory Effect ofJournal of tropical medicine · 2023Article
- Pomegranate (Journal of parasitology research · 2022Article
- Article
- Effect of methanolic extract fromVeterinary world · 2022Article
- Treatment of Human Babesiosis: Then and Now.Pathogens (Basel, Switzerland) · 2021Review
- Tafenoquine Is a Promising Drug Candidate for the Treatment of Babesiosis.Antimicrobial agents and chemotherapy · 2021Article
- Article
- Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo.Parasites & vectors · 2020Article
- Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection?The Journal of infectious diseases · 2019Article
- Evaluation of the in vitro and in vivo inhibitory effect of thymoquinone on piroplasm parasites.Parasites & vectors · 2019Article
- Inhibitory effects of fluoroquinolone antibiotics onInfection and drug resistance · 2018Article
- Performance and consistency of a fluorescence-based high-throughput screening assay for use in Babesia drug screening in mice.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The presently used therapy for Babesia microti infections, a combination of quinine and clindamycin, does not always result in parasitologic cures. To identify possible alternative chemotherapeutic agents for such infections, we screened, in the hamster-B. microti system, 12 antiprotozoal drugs that have either recently been released for human use or were in experimental stages of development at the Walter Reed Army Institute of Research for the treatment of malaria and leishmaniasis. Several well-recognized antimalarial drugs, such as mefloquine, halofantrine, artesunate, and artelenic acid, exhibited little or no effect on parasitemia. Two 8-aminoquinolines, WR006026 [8-(6-diethylaminohexylamino)-6-methoxy-4-methylquinoline dihydrochloride] and WR238605 [8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5 -(3-trifluoromethylphenoxy-7) quinoline succinate], produced clearance of patent parasitemia. Furthermore, blood from infected hamsters treated with WR238605 via an intramuscular injection failed to infect naive hamsters on subpassage, thus producing a parasitologic cure. These two compounds merit further screening in other systems and may prove useful in treating human babesiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.